Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant
Abstract
Share and Cite
Bento, D.; Jesus, S.; Lebre, F.; Gonçalves, T.; Borges, O. Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant. Pharmaceutics 2019, 11, 72. https://doi.org/10.3390/pharmaceutics11020072
Bento D, Jesus S, Lebre F, Gonçalves T, Borges O. Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant. Pharmaceutics. 2019; 11(2):72. https://doi.org/10.3390/pharmaceutics11020072
Chicago/Turabian StyleBento, Dulce, Sandra Jesus, Filipa Lebre, Teresa Gonçalves, and Olga Borges. 2019. "Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant" Pharmaceutics 11, no. 2: 72. https://doi.org/10.3390/pharmaceutics11020072
APA StyleBento, D., Jesus, S., Lebre, F., Gonçalves, T., & Borges, O. (2019). Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant. Pharmaceutics, 11(2), 72. https://doi.org/10.3390/pharmaceutics11020072